Table 3 Summary of DVH analysis for CTVs and PTVs.
From: Early clinical experience of radiotherapy of prostate cancer with volumetric modulated arc therapy
Parameter | Objectives | Group A | Group B |
|---|---|---|---|
CTV | |||
Volume [cm 3 ] | - | 62.0 ± 25.6 | 67.0 ± 29.6 |
Mean dose [%] | 99.5 ± 1.1 | 99.3 ± 0.5 | |
D 2% [%] | Minimise | 102.9 ± 0.8 | 102.6 ± 1.0 |
D 98% [%] | Maximise | 96.3 ± 2.0 | 96.4 ± 0.5 |
V 95% [%] | 100% | 97.1 ± 10.3 | 99.9 ± 0.2 |
V 107% [%] | - | 0.0 ± 0.0 | 0.0 ± 0.1 |
D 5% -D 95% [%] | Minimise | 5.4 ± 1.7 | 5.1 ± 0.9 |
PTVI (76-78 Gy) | |||
Volume [cm 3 ] | - | 185.4 ± 68.2 | 245.0 ± 64.7 |
Mean dose[%] | 100.0% | 100.0 ± 0.0 | 100.0 ± 0.0 |
D 2% [%] | Minimise | 103.9 ± 0.9 | 104.1 ± 0.6 |
D 98% [%] | > 95% | 95.9 ± 0.8 | 95.4 ± 1.3 |
V 95% [%] | > 98% | 98.9 ± 0.9 | 98.2 ± 1.7 |
V 107% [%] | 0% | 0.0 ± 0.1 | 0.1 ± 0.1 |
D 5% -D 95% [%] | Minimise | 6.2 ± 1.0 | 6.7 ± 1.3 |
CI 90% | 1 | 1.3 ± 0.4 | 1.2 ± 0.1 |
PTVII- PTVI (70Gy) | |||
Volume [cm 3 ] | - | 47.5 ± 41.7 | - |
Mean dose [%] | - | 101.3 ± 0.4 | - |
D 2% [%] | Minimise | 113.0 ± 1.4 | - |
D 98% [%] | > 95% | 96.9 ± 2.7 | - |
V 95% [%] | > 98% | 98.7 ± 1.3 | - |
D 5% -D 95% [%] | Minimise | 12.7 ± 2.4 | - |
CI 90% | 1 | 1.4 ± 0.1 | - |